In the interim analysis , time to first relapse was significantly different in favor of the paliperidone palmitate group vs the placebo group ( hazard ratio = 3.45 ; 95 % CI , 1.73-6 .88 ; P < .001 ) ; median time to relapse was 274 days for placebo but not estimable for 3-month paliperidone palmitate .